NYSE · Biotechnology

ADC Therapeutics S.A. (ADCT) Stock

$1.19 +3.48% NYSE: ADCT Healthcare

ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors.

Valuation

MetricValue
Price$1.19
Market Cap$151.36M
P/E Ratio-1.09
P/B Ratio-0.82
P/S Ratio1.85
EPS (TTM)$-1.12
52-Week High$4.98
52-Week Low$0.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE65.27%
ROA-47.00%
ROCE-52.64%
Gross Margin-134.57%
Operating Margin-133.33%
Net Margin-173.02%
Debt/Equity-0.54
Current Ratio4.37

Annual Financials (USD)

Metric20212022202320242025
Revenue$34.0M$210.0M$70.0M$71.0M$81.0M
Operating Profit$-262.0M$-123.0M$-166.0M$-131.0M$-108.0M
Net Profit$-230.0M$-157.0M$-240.0M$-158.0M$-143.0M
EPS$-3.00$-1.99$-2.94$-1.62$-1.12
Op Margin-771.6%-58.8%-238.6%-184.4%-133.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$618.0M$491.0M$355.0M$322.0M$323.0M
Total Liabilities$452.0M$411.0M$503.0M$525.0M$509.0M
Cash$467.0M$326.0M$279.0M$251.0M$261.0M
Borrowings$140.0M$130.0M$124.0M$123.0M$439.0M

Latest News

The Cancer Therapy Strategy VERAXA Is Betting the Company On Exec Edge · Jul 6, 2026 ADC Therapeutics Announces New Employee Inducement Grant PR Newswire · Jul 1, 2026 ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study MT Newswires · Jun 30, 2026 ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial PR Newswire · Jun 30, 2026 ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views Simply Wall St. · Jun 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-233.0M$-138.0M$-119.0M$-124.0M$-141.0M
Investing Cash Flow$-13.0M$-1.0M$-6.0M$-2.0M$0
Financing Cash Flow$219.0M$2.0M$74.0M$37.0M$-2.0M
Net Cash Flow$27.0M$-140.0M$-48.0M$-28.0M$10.0M
Free Cash Flow$-240.0M$-139.0M$-122.0M$-125.0M$-141.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.11
EV / EBITDA-0.37
FCF Yield-93.16%
Quick Ratio4.31
Interest Coverage-2.08
Return 1Y-63.28%
Return 3Y-18.54%
Return 5Y-94.59%

Ownership

Insiders Held14.47%
Institutions Held67.84%
Institutions Float Held79.32%
Institutional HolderSharesReport Date
Redmile Group, LLC15,470,5022026-03-31
TCG Crossover Management, LLC11,390,1752026-03-31
Prosight Management, Lp8,300,0002026-03-31
Blackrock Inc.6,250,7472026-03-31
Eventide Asset Management LLC5,701,6552026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALMS $26.38 -2.40% -7.40 $3.26B 0.00%
AUTLAutolus Therapeutics plc $1.46 -13.61% -1.35 — 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
LCTX $1.13 -0.88% -17.61 $281.71M 0.00%

About ADC Therapeutics S.A.

ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.

ADC Therapeutics S.A. is led by CEO Ameet Mallik, employs 263 people, headquartered in CH, publicly traded since 2020.

ADC Therapeutics S.A. (ADCT) stock trades at $1.19 with a market capitalization of $151.36M. The stock is valued at a price-to-earnings (P/E) ratio of -1.09, price-to-book of -0.82, price-to-sales of 1.85. Over the past 52 weeks the stock has ranged between $0.78 and $4.98, and currently trades 76.1% below its 52-week high.

On profitability, ADC Therapeutics S.A. generates a return on equity (ROE) of 65.27% — well above the market average, a sign of a high-quality business, return on capital employed of -52.64%, an operating margin of -133.33%, a net profit margin of -173.02%.

Official website: www.adctherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides